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On November 9 and 10, 2015, the International Conference
on Mesothelioma in Populations Exposed to Naturally
Occurring Asbestiform Fibers was held at the University of
Hawaii Cancer Center in Honolulu, Hawaii. The meeting was
cosponsored by the International Association for the Study
of Lung Cancer, and the agenda was designed with signiﬁ-
cant input from staff at the U.S. National Cancer Institute
and National Institute of Environmental Health Sciences. A
multidisciplinary group of participants presented updates
reﬂecting a range of disciplinary perspectives, including
mineralogy, geology, epidemiology, toxicology, biochem-
istry, molecular biology, genetics, public health, and clinical
oncology. The group identiﬁed knowledge gaps that are
barriers to preventing and treating malignant mesothelioma
(MM) and the required next steps to address barriers. This
manuscript reports the group’s efforts and focus on stra-
tegies to limit risk to the population and reduce the inci-
dence of MM. Four main topics were explored: genetic risk,
environmental exposure, biomarkers, and clinical in-
terventions. Genetics plays a critical role in MM when the
disease occurs in carriers of germline BRCA1 associated
protein 1 mutations. Moreover, it appears likely that, in
addition to BRCA1 associated protein 1, other yet unknown
genetic variants may also inﬂuence the individual risk for
development of MM, especially after exposure to asbestos
and related mineral ﬁbers. MM is an almost entirely pre-
ventable malignancy as it is most often caused by exposure
to commercial asbestos or mineral ﬁbers with asbestos-like
health effects, such as erionite. In the past in North America
and in Europe, the most prominent source of exposure was
related to occupation. Present regulations have reduced
occupational exposure in these countries; however, some
people continue to be exposed to previously installed
asbestos in older construction and other settings. Moreover,
an increasing number of people are being exposed in rural
areas that contain noncommercial asbestos, erionite, and
other mineral ﬁbers in soil or rock (termed naturally
occurring asbestos [NOA]) and are being developed. Public
health authorities, scientists, residents, and other affected
groups must work together in the areas where exposure to
asbestos, including NOA, has been documented in theenvironment to mitigate or reduce this exposure. Although a
blood biomarker validated to be effective for use in
screening and identifying MM at an early stage in asbestos/
NOA-exposed populations is not currently available, novel
biomarkers presented at the meeting, such as high mobility
group box 1 and ﬁbulin-3, are promising. There was general
agreement that current treatment for MM, which is based
on surgery and standard chemotherapy, has a modest effect
on the overall survival (OS), which remains dismal. Addi-
tionally, although much needed novel therapeutic ap-
proaches for MM are being developed and explored in
clinical trials, there is a critical need to invest in prevention
research, in which there is a great opportunity to reduce the
incidence and mortality from MM.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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The domestic and global burden of malignant meso-
thelioma (MM) remains substantial, with approximately
3200 cases per year in the United States1 and 34,000
estimated deaths worldwide in 2013, respectively.2
Despite encouraging advances in clarifying the underly-
ing etiologic mechanisms, developing biomarkers for
disease detection, and conducting novel clinical trials,
the outlook for most patients in whom MM is diagnosed
remains dismal.3,4 Thus, presently the best strategy to
reduce the terrible toll of MM is to prevent the disease
from ever occurring (primary prevention).
The six types of minerals forming ﬁbers that have
been used commercially and fall under the umbrella
term of asbestos include the serpentine mineral chryso-
tile and the ﬁbrous amphiboles cummingtonite-grunerite
(amosite asbestos), actinolite, anthophyllite, riebeckite
(crocidolite asbestos), and tremolite.5 Additionally,
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particles found in the natural environment and not
speciﬁed in regulations as “asbestos,” such as ﬁbers of
the minerals erionite, winchite, richterite, antigorite, and
ﬂuoro-edenite, have also been associated with MM.5
The main preventable cause of MM has been expo-
sure to commercial materials made or contaminated
with asbestos.6 Workplace exposure to commercial
asbestos has affected occupational groups such as in-
sulators and pipeﬁtters, and their families with indirect
“take-home” exposures transported by contaminated
items such as clothing and contamination of the living
environment from asbestos-containing products.7
Starting in the 1980s when the mining and commer-
cial use of these ﬁbers was tightly regulated in some
countries (e.g., the United States) and/or entirely pro-
hibited in others (e.g., Western European countries),
there was a drastic reduction in occupational exposure
to asbestos.8,9 However, asbestos continues to be used
in Russia and many of the former Soviet republics,
China, India, and many countries in the low- and
medium-income range. Moreover, some of these coun-
tries have increased the use of asbestos exponentially
in recent years, raising major concerns about a likely
future increase in MM.10
An emerging problem is exposure of some pop-
ulations residing in developing rural and desert areas to
noncommercial asbestos and other types of mineral ﬁ-
bers present in the environment that have asbestos-like
health effects.5,11,12 The most notorious among these are
ﬁbers of the mineral erionite, a naturally occurring
mineral ﬁber found in soil and rock that has been
associated with very high rates of MM in Turkey.12,13
Similarly, environmental exposure to the mineral ﬁber
ﬂuoro-edenite, an amphibole species that occurs in the
volcanic rock at the foot of the Etna volcano in Sicily,
Italy, was linked to excess cases of MM among the vil-
lagers of Biancavilla in Sicily, Italy. Experimental evi-
dence supports induction of peritoneal and pleural
mesotheliomas induced by ﬂuoro-edenite ﬁbers present
in Etnean volcanic material from Biancavilla.14 Fibers of
the mineral antigorite have been associated with an
epidemic of MM in New Caledonia,15 where it was found
in the gravel used to pave roads. These and other min-
eral ﬁbers capable of causing MM are found throughout
the United States, Europe, and many other parts of the
world. When asbestos or other naturally occurring
asbestos (NOA) are present in the environment, all age
groups are exposed. A particular concern is when
exposure begins in childhood, as this type of exposure
may be associated with a greater risk for development of
MM, because essentially all these individuals who reach
adulthood will live long enough for MM to develop
within the 30- to 60-year latency after exposure.Recent studies have demonstrated that BRCA1 asso-
ciated protein 1 (BAP1) germline mutations transmitted
over the course of multiple generations are associated
with a very high incidence of MM and other malig-
nancies.16–25 Multiple tumor types develop in family
members who inherit BAP1 mutations; in addition,
laboratory studies suggest that the incidence of MM
may be increased upon exposure to asbestos, possibly
even at levels too low to cause MM among the popula-
tion at large.26 Additional factors that have been asso-
ciated in some studies with the development of some
MM were not the focus of the meeting and are reviewed
elsewhere.27–29
Methods
This meeting was organized to critically review and
assess the strengths and weaknesses of new discoveries
linking genetic risk and environmental exposure to the
development of MM, the status of the current research,
the possible use of MM biomarkers in prevention and
early detection, and the beneﬁt of novel molecularly
based therapies versus standard clinical interventions.
The goal of the meeting was to determine whether it
would be possible to establish consensus among the
participating experts on the current status of research in
these areas and eventually propose speciﬁc actions/
guidelines to help further guide research and reduce the
burden of mesothelioma.
The meeting organizers included the current chair
(M.C.) and vice chair (S.K.) of the International Asso-
ciation for the Study of Lung Cancer Mesothelioma
Task Force and the following National Institutes of
Health staff: A.C. from the National Cancer Institute
(NCI) Center for Global Health, S.M. from the NCI
Clinical Investigations Branch, A.M. from the National
Institute of Environmental Health Sciences, and
A.W. from the NCI Center to Reduce Cancer Health
Disparities. The meeting organizers invited the meeting
participants, who are the coauthors of this manuscript.
The need to have a multidisciplinary international
team including some of the top experts in the ﬁeld
while keeping the number of participants within the
available budget drove the criteria for selecting the
meeting participants.
The meeting was held over a 2-day period and
comprised six sessions that were chaired by the
meeting organizers: Mineral Fiber Exposure and Rate
of Disease Worldwide (chaired by M.C.), Mineralogy of
Mesothelioma-Inducing Mineral Fibers (chaired by
A.M.), Mineral Fiber Pathogenesis and Genetics (chaired
by S.K.); Prevention and Early Detection (chaired by
A.C.), Mineral Fiber Toxicology and Evidence of Adverse
Health Effects from Exposure (chaired by A.W.) and
State of the Art of Mesothelioma Treatment (chaired by
August 2016 Consensus Report on Mesothelioma 1249S.M.). At the end of each session a 20-minute discussion
was held. A 2-hour discussion/consensus-generating
session was held on day 2 to review the current
status of the ﬁeld and the issues presented. Each
session chair wrote an initial draft summarizing the
presentations and discussions of their respective ses-
sion. After the meeting was completed, the organizers
spent an additional day writing the ﬁrst draft of the
manuscript. This initial draft was circulated among all
meeting participants multiple times until a ﬁnal
consensus manuscript was produced.
Genetic Risk
BAP1 is the ﬁrst, and to date the only, gene that
could increase the risk of cancer from asbestos and
erionite exposure. Dr. Carbone and his team ﬁrst
discovered that the risk for development of MM was
transmitted in an autosomal-dominant fashion in certain
Turkish families in which MM developed in more than
50% of members.13,30 In subsequent studies, the team
found that germline mutations in the BAP1 gene caused
a novel cancer syndrome characterized by extremely
high incidences of MM and uveal melanoma (UM)16 and,
less frequently, other cancers.31 Moreover, characteris-
tics of benign melanocytic skin lesions32 that were
initially considered part of the family of lesions known
as atypical Spitz tumors often develop in these in-
dividuals. Subsequent analyses demonstrated that these
lesions have unique histological and molecular charac-
teristics setting them apart from atypical Spitz tumors,
and they were named melanocytic BAP1-associated in-
tradermal tumors (MBAITs),31 a ﬁnding supported by
subsequent studies.33 The critical role of BAP1 in
MM pathogenesis was further highlighted by the ﬁnding
that BAP1 is the most frequently mutated gene in
sporadic MM.34–38
BAP1 is a deubiquitylase that associates in the nu-
cleus with multiprotein complexes regulating key
cellular pathways, including the transcription, DNA
replication, and DNA damage response pathways.39–49
All germline BAP1 mutations identiﬁed to date lead to
inactive forms of BAP1 lacking deubiquitylating activity
or to truncated variants that lack the nuclear localization
signal.50,51
At least one malignancy has developed in all carriers
of germline BAP1 mutations who are older than 55 years
studied so far, and multiple cancers have developed in
many of them.31 Familial MMs in these individuals occur
in either the pleura or peritoneum (frequency ratio 1:1)
at a median age of 56.3 years, have a male-to-female ratio
of 0.73:1, and are associated with prolonged survival of 5
to10 or more years, compared with a median age at
diagnosis of 72, a pleural-to-peritoneal ratio of 86:14, a
male-to-female ratio of 4:1, and a median survival of lessthan 1 year in sporadic MM.44 More than 50 families with
this mutated BAP1 cancer syndrome have been described
in the United States, Europe, and New Zealand.
In a large ongoing research effort to investigate
the mutated BAP1 cancer syndrome, Carbone et al.17
screened patients with family histories of multiple
MMs and melanomas. They identiﬁed four families that
shared an identical BAP1 mutation and lived in different
parts of the United States. After assessing family
histories taken at the patient’s bedside, genealogy, and
genetic analysis, they discovered a mutated BAP1 cancer
syndrome kindred of approximately 80,000 descendants,
whose family members descend from a couple born in
Germany in 1710 (the man) and 1712 (the woman).
The man’s ancestors were traced to Switzerland in 1588,
and they immigrated to Germany in the 17th century. In
the 18th century, the couple immigrated to the United
States and their descendants spread throughout the
country, with carriers of the mutation affected by
multiple malignancies.
These ﬁndings provide a guideline on how to inte-
grate genomic and genealogical studies to identify
additional branches of related families that may carry
germline BAP1 mutations and beneﬁt from genetic
counseling and interventions for early detection and
prevention.
Environmental Exposure
Environmental exposure to carcinogenic ﬁbrous
minerals includes indoor and outdoor contamination
caused by both asbestos-containing commercial mate-
rials and NOA. The term naturally occurring asbestos is
now widely used to describe potentially hazardous
asbestos-like ﬁbrous minerals that occur in rocks and
soils, are often present in concentrations far lower than
those necessary for mining, may or may not ﬁt the reg-
ulatory or industrial deﬁnitions of asbestos, and may
become airborne inhalation hazards after being aero-
solized by human activity or natural surface processes.52
Recent research suggests that NOA may be more com-
mon in our environment than previously thought.5,53
When conventional polarized light microscopy is
used, the concentration of NOA in soils is often lower
than the level of detection (<0.25%). However, when
these soils with low concentrations of NOA are
disturbed, potentially hazardous airborne exposures
can be generated.54,55 Accordingly, MM and other
asbestos-related diseases have been documented from
environmental exposure to NOA.5 Documenting envi-
ronmental exposures to NOA is much more challenging
than is documenting occupational exposures.5,11,12
Activity-based sampling measures concentrations of
airborne ﬁbers during typical human activities.11,54
Because human activities are an important factor in
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ronment, activity-based sampling is extremely impor-
tant to characterize and assess the health risks of
environmental exposures. Assessing exposure to NOA
requires testing for all potentially harmful ﬁbrous
minerals, not just those subject to government regula-
tion.11,53 Currently, most testing laboratories analyze
only the regulated minerals, and therefore, they can
often miss other mineral ﬁbers that also have patho-
genic importance.56,57
An alternative approach to investigating a high-risk
exposed population for the purpose of documenting
asbestos-like health effects is to screen people for benign
pleural disease, which has a higher prevalence and
shorter latency period than MM and can be detected by
radiographic imaging.58 Examples of this type of
research include using plain chest radiography to screen
the population of Libby, Montana, and chest computed
tomography to evaluate potential health effects among
workers in North Dakota who were exposed to
erionite.11,58
Which dose metric best predicts disease risk is un-
clear. Although exposure to the six types of mineral ﬁ-
bers classiﬁed and regulated as “asbestos” has long been
recognized as a causative factor in a spectrum of pul-
monary and thoracic diseases, our understanding of the
speciﬁc physiochemical risk factors associated with such
adverse health effects has been limited by the analytical
methods typically used to measure and describes expo-
sures (i.e., using light microscopy techniques that count
only a subpopulation of the actual airborne ﬁber expo-
sure and truncating analyses to only the six minerals
typically regulated as “asbestos”). Use of higher-quality
analytical technologies such as transmission electron
microscope analyses57 and better ﬁber counting rules
would help us to better understand how ﬁber charac-
teristics (e.g., chemistry, size, shape, surface area, etc.)
are related to toxicity and risk of disease. Moreover, use
of improved technologies and assessment approaches
would greatly enhance our understanding of risk from
exposure to other NOA-like mineral ﬁbers, such as
erionite, winchite, richterite, antigorite, ﬂuoro-edenite,
and other potentially carcinogenic mineral ﬁbers that
are not presently included in most analyses of exposure.
Suboptimal and incomplete assessment of exposure in-
terferes with our ability to assess the possible impact of
NOA on risk for MM development of and other
“asbestos”-related diseases. Several reviews and articles
describe the proper methodology to detect both asbestos
and NOA, and we refer to them for a detailed
discussion.52,56
Research has been unable to clearly attribute adverse
health effects to speciﬁc mineral ﬁber characteristics.
Minerals known to be associated with MM are able todisplay a ﬁbrous morphologic pattern, which is a direct
result of their atomic structure. However, in nature,
these minerals rarely occur as homogenous mineral
deposits and exist as a continuum of particles of
varying size, shape, crystalline structure, and chemical
composition, which may or may not be further altered by
natural environmental processes such as physical and
chemical weathering.56,59 This presents difﬁculty in un-
derstanding potential health risks attributable to speciﬁc
natural mineral ﬁbers. Determining cancer etiology is an
intricate process because data from molecular biology,
genetics, in vivo experiments, and epidemiology must be
synthesized to gain a complete understanding of carci-
nogenicity.60 Because of mixed and incomplete charac-
terization of exposures in many studies, it has been
difﬁcult to relate speciﬁc adverse effects to speciﬁc sizes
and types of ﬁbers, etc. For example, the length and
aspect ratio of ﬁbers appear to be critical, with several
studies demonstrating that greater toxic effects occur
with longer ﬁbers or greater aspect ratios. Longer ﬁbers
are retained for longer times in human lungs and thus
exert their carcinogenic effect over the course of many
years, whereas shorter ﬁbers have a relatively more
rapid turnover.61 However, given a sufﬁcient dose, ﬁbers
with a shorter or lower aspect ratio may still exert
certain toxic effects, such as acute inﬂammation and
ﬁbrotic changes.62 Experimental studies comparing lung
function responses to NOA samples found that chrysotile
was as ﬁbrogenic as amphibole ﬁbers and had detri-
mental effects on lung function63; however, epidemio-
logical studies indicate a lower risk for development of
MM from exposure to chrysotile than from exposure to
amphiboles.6 In addition, studies of some other elon-
gated mineral ﬁbers, such as palygorskite, showed no
substantive health effects.64
Studies regarding the mode of action of asbestos ﬁ-
bers indicate that mesothelial cells and macrophages,
which are present in large numbers around asbestos
deposits in the lung, produce a variety of deleterious
mediators. These include high mobility group box 1
(HMGB1) and other cytokines, reactive oxygen species,
and growth factors that promote sustained cell injury,
inﬂammation, and DNA damage and stimulate cell
growth, leading to ﬁbrosis and/or carcinogenesis.65–72
Another approach to analyzing ﬁber exposure is to
evaluate the mineral ﬁber content in the lung tissue of
people with known exposure.7,61,73 Some prior work has
been done to assess exposures from the natural envi-
ronment by evaluating ﬁber content in sentinel animal
species, such as wild rats.74 One possible research
strategy to assess the associations between ﬁbers
deposited in lung and MM, is to harvest lung tissue at the
time of lung resections or at autopsy from patients with
MM and from resident controls without MM. This type of
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1000 ﬁbers per gram (amphibole ﬁbers longer than
5 mm) in the United Kingdom, with no signiﬁcant dif-
ference between amosite and crocidolite.73 However,
this type of research effort is fraught with challenges; for
example, in the United States it has become increasingly
difﬁcult to obtain such samples, as autopsies are rare
and medicolegal issues and lawyers often interfere with
research efforts to obtain and study lung samples.
Moreover, care must be taken in the interpretation of
ﬁndings: all ﬁbers, including asbestos and NOA, should
be studied, and ﬁber populations retained in the lung
may change over the long latency period between inha-
lation and development of MM. In this regard, it is
generally accepted that some ﬁbers such as chrysotile
are digested by tissue macrophages and removed from
the human lungs more quickly than are other ﬁbers such
as crocidolite and erionite, and that among these ﬁbers,
the longer the ﬁber, the longer they are retained in the
lungs. It has been estimated that crocidolite has a half-
life retention time in human lungs of 7 to 9 years61,75
and that chrysotile is cleared faster, with a half-life
retention in the lungs that was estimated from weeks
or months76 to 1 to 8 years, depending on the length of
its ﬁbers.77
Several epidemiological features are emerging that
may indicate differences between patients with MM who
had environmental exposure or genetic risk factors and
patients with MM who are known to have had occupa-
tional exposure. MM caused by environmental exposure
and/or reported in those with BAP1 genetic mutations
are more likely to be found in younger individuals and to
have equal sex and pleural/peritoneal distributions.
These clinical observations have been seen in the cases
of MM occurring in Cappadocia, Turkey, and in New
Caledonia, as well as among cases of MM occurring in
families carrying BAP1 germline mutations.17,44
In eastern China, the pattern of MM reported by Dr.
Weimin Mao appears unique, with an unusual excess of
peritoneal MM (pleural-to-peritoneal ratio of 1:2), fe-
male cases (male-to-female ratio of 1:2), and young age
(<50 years). Direct occupational or occupationally
related take-home exposures have been documented in
only 12% of these cases. The cause in the remaining 88%
of this series of Chinese patients is unclear, and studies
to clarify whether issues such as environmental expo-
sure to mineral ﬁbers and possibly other agents, genetic
risk factors, etc., underlie development of MM in this
population are greatly needed. The Chinese ﬁndings are
of exceptional interest, as they potentially point to a
different set of events and etiologic factors that cause
development of MM in predominantly young Asian
women who have no occupational exposure to asbestos.
Identifying the cause(s) of MM in these Chinese womenis critical to developing speciﬁc preventive and thera-
peutic approaches to MM in this population. These
studies may also help us understand the causes of MM
(in particular, peritoneal MM) in young women with no
apparent history of asbestos exposure, as an increasing
number of such cases are also coming to our attention in
the United States and Europe. For example, Lee et al.
reported that of 64 patients (35 females and 29 males)
with peritoneal MM, only ﬁve (8%) had a prior history of
asbestos exposure. Of interest, 24 of 64 of these patients
(38%) had had a prior abdominal operation, which was
identiﬁed as a risk factor in this study, suggesting the
hypothesis that the inﬂammation related to the opera-
tion may have promoted the MM growth. Two patients
had had radiation exposure and 31 had no known risk
factors at all.78
Another lesson from the Chinese and European ex-
periences is the need to carefully conﬁrm diagnoses of
MM by using state-of-the-art pathology techniques. An
older study by Goldberg et al. reported that 33% of the
diagnoses of MM in France could not be conﬁrmed by an
expert review panel.79 At the conference, Dr. Pira et al. in
Italy and Dr. Mao et al. in China reported a similar or
higher percentage of erroneous diagnoses of MM that
were often related to inadequate specimens: diagnoses
based on cytologic examination or ﬁne-needle aspiration
rather than larger biopsy, diagnoses that were not sup-
ported by an adequate set of immunostains, or diagnoses
made by pathologists or coroners (in the United States)
who rarely see these malignancies. Therefore, in addition
to precise assessment of exposure, accurate diagnosis of
MM is greatly needed to ensure that cases of MM are not
missed owing to erroneous diagnosis and to prevent
misunderstanding of the etiology, clinical care, and po-
tential for prevention by the inclusion of non-MM cases.Biomarkers
Novel Potential Biomarkers of Asbestos
Exposure and MM
HMGB1 is a damage-associated molecular pattern
nuclear protein that is released by human mesothelial
cells and macrophages undergoing programmed cell
necrosis after exposure to asbestos ﬁbers.68 HMGB1
triggers the inﬂammatory response that over the years
contributes to the development of MM.80 Moreover, as
MM grows out of an environment rich in HMGB1, MM
cells are often “addicted” to HMGB1 and actively secrete
HMGB1 in the extracellular space in which HMGB1
promotes MM tumor cell growth and invasion.81 HMGB1
secretion requires its acetylation, which prevents the
normal transport of HMGB1 from the cytoplasm to the
nucleus. Patients who have documented exposure to
asbestos have increased levels of HMGB1 in the serum80–83;
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cantly higher than in individuals who were not exposed
to asbestos or smokers with bronchial dysplasia and
chronic inﬂammation. In asbestos-exposed individuals,
most of the HMGB1 found in the serum is in the non-
acetylated form, as is expected after passive release of
HMGB1 on account of necrotic cell death induced by
asbestos. The levels of HMGB1 are also increased in
patients with MM patients to even higher levels than in
asbestos workers, and most importantly, the serum of
MM patients contains almost exclusively the hyper-
acetylated form of HMGB1 and MM cells actively
secrete HMGB1 to promote their own growth.84 Pres-
ence of total and hyperacetylated HMGB1 was also
sensitive and speciﬁc in identifying which patients with
pleural effusions had a malignant effusion due to MM
and which had benign or metastatic disease to the
pleura. Among patients with malignant pleural effu-
sions, sensitivity and speciﬁcity were increased when
HMGB1 and ﬁbulin-3 (see later) were measured
together.
Additional potential novel biomarkers for MM include
SOMAmers (SomaLogic, Inc., Boulder, CO), which are
speciﬁcally designed short pieces of nucleic acids that
bind selectively and speciﬁcally to individual proteins.
Individual SOMAMer-predicted proteins have been vali-
dated using commercially available enzyme-linked
immunosorbent assays, and among them, the most
promising is the SomaLogic 13 marker proﬁle.85 In a
head-to-head comparison with soluble mesothelin–
related protein (SMRP) with identical specimens, the
SomaLogic proﬁle had much greater sensitivity and
speciﬁcity. Further validation studies using serum from
cases with other malignancies compared with MM using
a 13-marker panel is ongoing.
Biomarkers Studied for Early Detection and
Diagnosis
Most of the biomarkers have been studied exclusively
in pleural as opposed to peritoneal mesothelioma.
After the groundbreaking work from Robinson et al.
describing the use of SMRP for the diagnosis of MM
in the Wittenoom Cohort of Western Australia,86 the
laboratories of Dr. Pass and Dr. Robinson performed a
blinded SMRP validation of 817 asbestos-exposed in-
dividuals versus 168 people with MM (manuscript in
preparation). This trial, with the SMRP measured blindly
at two separate laboratories, validated in the area under
the curve (AUC) of the receiver operating characteristic
curve of 0.80 not only in the entire cohort but also in
patients with stage I or II disease. Hollevoet et al. pub-
lished an individual patient data meta-analysis of 1026
cases of MMs and 3465 controls based on data from 16
studies in the literature and further conﬁrmed an AUC of0.80.87 An NCI Early Detection Research Network–
sponsored assessment of the Vitamin C and Retinoic Acid
study, in which 49 cases of MM were diagnosed in 3897
asbestos-exposed individuals who contributed sera for
the chemoprevention study, revealed that the receiver
operating characteristic of these 49 cases could generate
an AUC of 0.72 at 1 year before the diagnosis when
prediagnostic sera from these patients were used
(manuscript in preparation). When the SMRP compari-
sons were performed any longer than 1 year before
diagnosis, the ability to detect the disease was unsatis-
factory. It was concluded that SMRP is a robust marker
with good speciﬁcity, but its sensitivity (32% at 95%)
has so far limited its application for early detection of
MM in longitudinal follow-up of high-risk cohorts.87
Osteopontin (OPN) has also shown signiﬁcant fold
increases in MM compared with in controls, with
ninefold increases documented (p < 2  10-13). Indeed,
the original manuscript described remarkable AUCs
close to 0.9 for serum OPN.88 Unfortunately, it was
learned that OPN is not speciﬁc for MM. Moreover, the
inability of some laboratories to reproduce the results
from the original paper was due to the fact that a
thrombin cleavage molecule affected the levels of OPN
measured when the measurement was performed in
serum89 and to the fact that OPN enzyme-linked
immunosorbent assays differed in reliability. Subse-
quent investigators conﬁrmed these ﬁndings by
measuring OPN in plasma from malignant pleural me-
sotheliomas (MPMs) and control populations with a
rise in the AUC to levels comparable to the rise in
SMRP.90–92
Other markers, including ﬁbronectin and thrombo-
spondin, have been examined. The most promising
seems to be a member of the ﬁbulin family, ﬁbulin 3
(FBLN3), the gene of which is EGF-containing ﬁbulin-
like extracellular matrix protein 1 gene (EFEMP1).93 In
the available literature, FBLN3 was found to be
decreased in most tumors compared with normal tissue
on account of methylation, whereas in MM, Pass et al.
found that it was increased sevenfold (p ¼ 10-9)
compared with normal mesothelium. Fibulin upregula-
tion in MM was validated in silico by examining FBLN3
on expression arrays.93 When MPM cohorts from
Detroit and New York were used, the AUC for FBLN3
compared with any controls was consistently greater
than 0.95 and maintained 94% speciﬁcity at 100%
sensitivity for stage I or II lung cancers. Levels of
FBLN3 fell after successful cytoreduction and increased
at the time of progression. A blinded validation from the
Princess Margaret Cancer Centre in Canada maintained
an AUC of 0.87. Moreover, pleural effusion FBLN3 was
markedly increased and speciﬁc for MM effusions
compared with benign effusions and effusions from
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versy persists regarding the role of FBLN3 in MM, with
some reports validating the original publication94 and
failure to validate in others.95–98 Validation of these
early detection markers, as well as others involving
microRNAs99 in other study populations, is the next
pressing issue.
Clinical Interventions
MM is heterogeneous in its clinical behavior according
to sex, histological features, primary site of disease, and
stage.78,100–103 Although distant metastasis may occur,3
most of the morbidity and mortality is due to local dis-
ease progression. Most of the available clinical information
about treatment of early-stage MPM is derived from
retrospective single-center series, and thus there is no
consensus as to the optimal treatment.104,105 The combi-
nation of pemetrexed and platinum is the only U.S. Food
and Drug Administration (FDA)-approved regimen for pa-
tients with MPM who are either unresectable or otherwise
not candidates for an operation. The recent French Meso-
theliomaAvastin Cisplatin Pemetrexed Study trial reported
that the addition of bevacizumab to platinum-pemetrexed
improved survival outcomes for patients with MM; how-
ever, this agent has not yet obtained FDA approval.
Although patients in whom MM was diagnosed and
who were treated when it was in stage 1A experience
survival of 3 or more years, in more than 95% of patients
the diagnosis is made at a later stage, when median sur-
vival remains approximately 1 year from diagnosis.3 The
possible beneﬁcial role of surgical resection in MPM re-
mains controversial. The Mesothelioma and Radical Sur-
gery trial from the United Kingdom provided the only
randomized assessment of surgical management of MM
and showed no additional survival beneﬁt from an oper-
ation; actually, patients who had an operation did worse
than those who were treated with only chemo-
therapy.106,107 This trial was highly debated by experts in
the ﬁeld. The trial was not designed to answer the ques-
tion of whether to perform an operation (only for the
feasibility to randomize), and furthermore, the perioper-
ative mortality rates were not acceptable and not repre-
sentative. However, for selected patients with MM (those
with early-stage disease, a good performance status, and
epithelioid histologic ﬁndings and for whom the surgeon
believes achieving a macroscopic cytoreduction [MCR] is
possible), an operation is usually recommended.108 The
speciﬁc surgical procedure that accomplishes the MCR
should be clearly deﬁned according to the deﬁnitions of
Rice et al.109 There is no survival advantage to an R2
surgical resection that does not achieve complete macro-
scopic cytoreduction. Patients with MM who were
selected for surgical resection as part of a trimodality
treatment approach had median survival rates of 33.2months if MCR (R0 or R1) was possible versus 12.9
months in patients for whom only an R2 resection was
possible.110 These survival differences reﬂect the impact
of both the pathologic stage and extent of tumor at the
time of surgery, as well as the importance of achieving
complete local disease control. Therefore, if an R0 or R1
MCR cannot be achieved, local tumor control is not
possible and there is little survival beneﬁt to the opera-
tion. In the absence of symptoms, these patients are better
served with systemic therapies to treat all foci of disease
and spared the morbidity of a major surgical resection.
The role of an operation in MM for the purposes of
symptom palliation for indications of persistently trapped
lung or debulking of macroscopic disease remains
pivotal.111 Extrapleural pneumonectomy (EPP) with en
bloc resection of the lung with the parietal and visceral
pleural, pericardium, and diaphragm or lung-sparing
pleurectomy/decortication (P/D), in which all macro-
scopic tumor on the parietal and visceral pleura is
removed, are the two surgical procedures typically per-
formed; these aggressive procedures should be per-
formed by surgeons and in centers with appropriate
expertise in these procedures.3,112 There are no random-
ized trials that compare EPP with P/D, but retrospective
analyses suggest that survival outcomes are similar and
the choice of a speciﬁc procedure—EPP or P/D—is usu-
ally dictated by the surgeon’s expertise.3 Many things
factor into the decision for EPP rather than P/D, including
patient functional status, patients’ desires after coun-
seling, and which operation ﬁts the preoperative or
postoperative adjuvant protocols prescribed. A retro-
spective review of 663 patients who underwent an oper-
ation at three MM centers in the United States compared
EPPwith P/D and found that patientswho underwent P/D
had better survival than those who underwent EPP and
that perioperative morbidity and mortality was greater
after EPP.3 The morbidity and mortality conclusions from
this study have been validated by analyzing data from the
Society of Thoracic Surgeons database.112
In patients with resectable MM, a trimodality
approach is often used with radiation therapy to enhance
local disease control and chemotherapy (systemic, either
preoperative or postoperative, or intraoperative) to
reduce the risk of local recurrence and systemic metas-
tases. Although an OS advantage has not been demon-
strated with these combined approaches in a
randomized trial, this trimodality approach has been
associated with relatively prolonged survival compared
with chemotherapy alone as historical controls.113–118
Nevertheless, a recent randomized trial has questioned
the beneﬁt of postoperative radiation therapy after
extrapleural pneumonectomy.119
In the United States, it is standard practice to
administer four cycles of cisplatin-pemetrexed to
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Ultimately, the decision to administer neoadjuvant or
adjuvant systemic therapy should be made in a multi-
disciplinary setting. Neoadjuvant therapy has the
inherent risk of adversely delaying the operation or
causing complications, with the EPP completion rates
ranging between 42% and 84%.116,118,120–125 On the
other hand, neoadjuvant therapy yields response rates
between 29% and 44%116,118 and can give prognostic
information, with responders having better survival
outcomes.116 Adjuvant chemotherapy does not compro-
mise surgical resection, but poor patient tolerance after
an operation and radiation often preclude delivery of
chemotherapy. To date, there have been no randomized
trials comparing neoadjuvant or adjuvant therapy, and
both approaches are accepted as standard practice.
Although trimodality therapy is standard practice,
both neoadjuvant and adjuvant studies still yield
median OS rates between only 16.6 and 25.5
months.116,118,120,121,123,125–127 There is a clear need for
the addition of novel agents or immunotherapies to tri-
modality treatment to improve survival outcomes. These
agents must improve response rates, have reasonably low
toxicity proﬁles with no compromise of trimodality
treatment, and be able to be administered in a mainte-
nance setting. In addition, the trial designs should include
tissue and radiographic correlates to facilitate develop-
ment of predictive and prognostic biomarkers.
In the unresectable setting, the Mesothelioma Avastin
Cisplatin Pemetrexed Study trial was discussed. This
phase III trial was conducted by the Intergroupe Fran-
cophone de Cancerologie Thoracique; it randomized 448
chemonaive unresectable MPMs to platinum-pemetrexed
(PC) n¼ 225) versus platinum-pemetrexed-bevacizumab
(PCB) (n ¼ 223).128 The PC was given for six cycles in
both arms and the bevacizumab was given for six cycles
with chemotherapy and then continued as maintenance.
PCB improved both progression-free survival (hazard
risk ¼ 0.61, p < 0.0001) and OS over PC (hazard risk ¼
0.77, p ¼ 0.0167). The median OS was 18.8 months with
PCB compared with 16.1 months for PC. The median
progression-free survival was 9.2 months with PCB
compared with 7.3 months with PC. This triplet regimen
is in the process of undergoing evaluation by both Eu-
ropean and U.S. regulatory agencies for approval. It
would be the ﬁrst novel agent approved for use in me-
sothelioma. In the frontline maintenance space, other
agents have not succeeded. The Control of Mesothelioma
with Maintenance Defactinib trial was a registration-
directed phase II trial of maintenance therapy with a
focal adhesion kinase inhibitor defactinib (VS-6063) in
patients with MPM that unfortunately closed in
September 2015 because of lack of efﬁcacy.A number of novel treatments for nonresectable MM
that look promising at the exploratory stages are in
clinical trials.129 Mesothelin has been validated as an
attractive target for cancer therapy. Several drugs tar-
geting mesothelin, including immunotoxins (SS1P and
RG7787),130 a chimeric monoclonal antibody (amatux-
imab),131 an antibody drug conjugate (anetumab rav-
tansine),132 and a tumor vaccine (CRS-207), are in
various stages of development to treat patients with
mesothelin-expressing tumors, including MM. A phase
II/III randomized clinical of amatuximab in combination
with pemetrexed and cisplatin is currently open as
frontline therapy for patients with pleural MM who are
not candidates for an operation. Registration clinical
trials of anetumab ravtansine and CRS-207,133 a live
attenuated Listeria monocytogenes engineered to express
human mesothelin, are expected to open soon.
Checkpoint immunotherapies are also under investi-
gation in unresectable mesothelioma. A mesothelioma
cohort of KEYNOTE-028 (n ¼ 25), which included only
patients whose tumors were positive for PD-L1 expres-
sion and used pembrolizumab (a programmed cell death
protein 1 inhibitor) reported a 24% overall response
rate, 48% stable disease rate, and 76% disease control
rate. This study is ongoing and accruing patients with
unresectable mesothelioma.134 However, immunother-
apies require further investigation despite the initial
promising results. A cytotoxic T-lymphocyte antigen-4
inhibitor, tremelimumab, was recently assessed in a
randomized phase II trial (DETERMINE) in the salvage
setting and was unfortunately a negative trial when
compared with placebo (AstraZeneca press release).135
Patient advocacy efforts supported by the Mesotheli-
omaAssociationResearch Foundation have resulted in the
introduction in the U.S. Congress of a bill to establish an
MM patient registry. High-quality data from such a regis-
try are essential in providing data to evaluate patient
outcome, quality of life, and follow-up information;
calculate survival rates; analyze referral patterns; allocate
resources at the regional or state level; report cancer
incidence; and identify unmet MM research needs.
The clinical session concluded with the consensus
that because of the relative rarity of the disease, multi-
disciplinary international efforts are needed to conduct
and complete randomized clinical trials with clinically
meaningful end points.
Findings and Actionable Guidelines to
Reduce the Future Incidence of MM
The ﬁnding that BAP1 heterozygosity renders mice
susceptible to low amounts of asbestos that rarely cause
MM in wild-type mice supports the biologic plausibility
for a similar activity in humans.26 To date, none of the
patients with MM who are germline carriers of BAP1
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to asbestos, indicating that MM can develop in these
individuals with undetectable levels of exposure. How-
ever, on the basis of the study by Napolitano et al.26
showing that MM developed in 30% of BAP1þ/- mice
when they were exposed to 0.5 mg of asbestos
(an amount that rarely caused MM in wild-type
control mice) and on the basis of a study by the team
of J. R. Testa, as described by Xu et al.136 showing that
BAP1þ/- mice exposed to 3 mg of asbestos have a higher
incidence of MM than control mice, it is anticipated that
carriers of germline BAP1 mutations may be more sen-
sitive than the population at large to low amounts of
asbestos and NOA. It is therefore a reasonable precau-
tion for germline carriers of the BAP1 mutation to
consider avoiding jobs associated with any possible
asbestos exposure, including low levels of exposure, and
avoiding residing in areas where asbestos and NOA are
known to be present in the environment. Suggested
guidelines for BAP1 testing and monitoring of those
found to have germline BAP1 mutations are listed later
in this article. Moreover, the presence of BAP1 mutations
offers new potential therapeutic targets.137 For example,
BAP1 regulates the expression of histone deacetylases,
and assessment of BAP1 may help identify patients who
may be more likely to respond to histone deacetylase
inhibitors.138
Further research is needed to understand the relative
contribution of physiochemical characteristics (e.g.,
mineralogy,morphology, and surface area) to the toxicityof
diverse natural mineral ﬁbers.139 Each of these attributes
may inﬂuence ﬁber durability, deposition, and clearance
and thus persistence in the body and subsequent devel-
opment of disease. Inherent bioreactivity due to mineral
ﬁber composition will further inﬂuence toxicity. Therefore,
to ultimately understand the risks of exposure and prevent
disease, it will be important to fully understand the con-
centrations and characteristics of the elongated mineral
particles that are being inhaled by those at risk, carefully
evaluate physiologic responses, and develop new dose-
response metrics associated with earlier upstream bio-
markers of exposure to reduce adverse health effects.
Intervention to reduce exposure has great potential
to prevent development of MM and save lives. For
example, even though much remains to be learned about
environmental exposure to noncommercial mineral ﬁ-
bers with asbestos-like health effects, examples exist in
which sufﬁcient evidence was developed to motivate
public health action to protect exposed populations.
When Cappadocia, Turkey, was faced with an outbreak
in which MM developed in and caused the death of 50%
of exposed people, the government intervened and,
following the advice of scientists, built two new small
villages to help eliminate environmental exposure of thepopulation to erionite ﬁbers.12 In Libby, Montana, the
Environmental Protection Agency took the unprece-
dented step of declaring a public health emergency and
engaging in aggressive environmental cleanup during
which contaminated surface soils were removed and
replaced with clean ﬁll (http://www2.epa.gov/region8/
cleanup-activities-libby). Similar types of actions, albeit
on a much smaller scale, have been performed around
schools in El Dorado, California, and at Superfund sites
across the United States. Off-road vehicle use, which
produces air exposure to dust-containing carcinogenic
mineral ﬁbers, and public access have been restricted at
Clear Creek, California.54 The Calivaras Dam project in
California rigorously monitors and controls worker
exposure, as well as efforts to understand and reduce
emissions that may affect the surrounding community
(http://www.sfwater.org/modules/showdocument.aspx?
documentid¼4851). Fairfax County, Virginia, has
publicly mapped areas of asbestos throughout the
county and imposes various requirements for develop-
ment and control of emissions (http://www.
fairfaxcounty.gov/hd/chs/natural-asb.htm). In North
Dakota, after the ﬁnding of widespread erionite
contamination on more than 300 miles of gravel-
containing erionite roads that led to air erionite con-
centrations in school buses similar to concentrations
found in the MM villages in Cappadocia,11 the state
intervened to repave roads, schoolyards, etc., with
erionite-free gravel. Moreover, the North Dakota
Department of Health is working with counties and
businesses to restrict use of erionite-containing gravel
(https://www.ndhealth.gov/EHS/Erionite/).
In southern Nevada, after the ﬁnding of asbestos
(mainly actinolite) and other NOA (erionite, winchite,
richeterite, and magnesioriebekite) in the environment,
especially in the area surrounding the city of Las
Vegas,59 and the parallel ﬁnding of an unusually high
percentage of MM cases in young individuals living in the
same area,140 some initial steps are being taken to pro-
tect road construction workers from exposure caused by
disturbing asbestos in place. Although these initial steps
are encouraging, more should be done, including map-
ping precisely where the cases of MM in young in-
dividuals have occurred and studying the environment
near their homes. It is also urgent to precisely map
where mineral ﬁbers with asbestos-like health effects
are found, so that measures can be implemented to
prevent human activities that disturb and aerosolize the
ﬁbers (such as off road-vehicle recreation, housing
development, etc.) in those areas. Because ﬁbers travel
in the air, activities that disturb asbestos and NOA pre-
sent in the environment lead to potentially high levels of
exposure not only for those present in the area but
potentially also for people living miles away, because
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Ongoing exposure to asbestos and other hazardous
mineral ﬁbers in the environment underscores the need
to base worker and community protections on an
improved understanding of the speciﬁc physiochemical
characteristics (i.e., morphology, surface area, and bio-
persistence) and dose that make these ﬁbers hazardous
from the standpoints of both cancer and noncancer
health effects. Therefore, geological areas of concern for
exposure to asbestos and NOA must be mapped and the
associated exposures (i.e., activity-based exposures)
measured. Once the presence of asbestos and related
mineral ﬁbers in the environment has been documented,
a range of remediation and source control strategies can
be implemented to help reduce exposures. Understand-
ing that in some areas proximity to large deposits of
asbestos and erionite exposure cannot be entirely elim-
inated, it is reasonable to predict that measures aimed at
reducing exposure might save many lives in future
generations that would otherwise be lost.
It is often argued that there are costs associated with
preventive activities. From a humanitarian point of view,
however, MM is a horrible way to die; thus, MM pre-
vention is easily justiﬁable. From a purely economic
point of view, these measures are also justiﬁable: it has
been estimated that litigation costs the U.S. economy
billions of dollars per year, and many large companies
have gone into bankruptcy because of this litigation,
resulting in tens of thousands of jobs lost.141 Moreover,
the costs associated with the treatment of patients with
MM are upward of hundreds of thousand dollars per
patient. It is easy to recognize that an investment toward
reducing exposure to asbestos and NOA will result in
signiﬁcant economic return in the following decades—
and most importantly, will save many lives.
More research is needed to address several practical
questions and improve prevention. To start, among the
approximately 400 mineral ﬁbers present in nature, we
need to identify those that have asbestos-like health ef-
fects and thus need to be included in exposure assess-
ment and control. Also, we must conduct studies to
establish at what level of exposure these mineral ﬁbers
can be considered acceptably safe. And we need to
identify what are the most appropriate and effective
strategies to reduce risk by controlling exposures.
In addition to preventing development of disease by
preventing exposure, another approach to reduce the
burden of MM is to improve disease outcome through
early detection. In one study, HMGB1 produced an area
under the curve (AUC) of 1.0 and a sensitivity and
speciﬁcity of 100% to identify patients with MM. The
potential impact of this research is signiﬁcant because if
the ﬁndings of Napolitano et al.84 are independentlyvalidated, total HMGB1 could provide a useful blood
biomarker to identify individuals who have been
exposed to asbestos and are thus at risk for development
of MM, and, among them, hyperacetylated HMGB1 could
provide a blood biomarker to detect those in whom MM
has developed. The role of these biomarkers for the
prediagnosis of MM will, it is hoped, be addressed using
the cohorts of the Prostate, Lung, Colon, and Ovarian
Cancer Screening Trial in the near future. A clinical trial
sponsored by the NCI Early Detection Research Network
to validate HMGB1, as well as OPN, FBLN3, and SMRP, as
biomarkers for the early detection of MM is planned for
initiation in 2017.
Consensus Findings: Summary
Suggested Guidelines for BAP1 Genetic
Screening
1. The group supported BAP1 screening of patients with
MM occurring in the setting of a high-risk family
history of MM, UM, cutaneous melanoma, renal cell
carcinoma, cholangiocarcinoma, and basal cell carci-
noma and/or a high family incidence of multiple
cancers and patients with MM carrying melanocytic
BAP1-mutated atypical intradermal tumors known as
MBAITs.
2. Because of economic concerns, the group was divided
on the issue of screening for BAP1 germline mutations
in all sporadic cases of MM in the absence of MBAITS,
UM, etc., or in the absence of a suggestive family
history. Ideally, all patients with MM should be
screened for BAP1 germline mutations when the re-
sources are available.
3. The group supported screening for BAP1 germline
mutations in families with high-risk features, such as
three or more cases of any of the following cancers
within two generations: MM, UM, renal cell carcinoma,
and cholangiocarcinoma.
4. With regard to when to test, the group was supportive
of “early”-age screening for BAP1 germline mutations.
The exact “early” age of testing for BAP1 mutations
was controversial. It was noted that the earliest mel-
anoma detected in a BAP1-mutated germline carrier
so far has been at the age of 19 years (this individual
was cured by resection). In other cancer syndromes,
such as the Lynch syndrome, it is generally advised to
initiate screening 10 years before the earliest detected
cancer. Thus, it was proposed that children may
beneﬁt from genetic testing, as those who are found to
have inherited BAP1 mutations may beneﬁt from
screening for melanoma.
5. In summary, the group was in support of medical
screening for at-risk people who are carriers of
BAP1 germline mutations as follows: (1) annual
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noma at age 18 or younger; (2) annual eye examina-
tion/ophthalmoscopy for UM at age 18 or younger;
and (3) skin and eye examinations every 6 months
after age of 30, when the frequency of cancer among
carriers of germline BAP1 mutations starts to
increase.
6. Genetic counseling should be offered to all individuals
tested for BAP1.
7. Those with BAP1 germline mutations should be
encouraged to participate in studies to improve early
detection of MM (e.g., the planned biomarker studies).
The group identiﬁed this population as a high-risk
cohort in which early detection was greatly needed,
and because of the high incidence of MM, the clinical
effectiveness of novel MM therapies may be easier to
demonstrate.
8. Insurance does not cover next-generation sequencing
for MM. The group identiﬁed this issue as an impor-
tant barrier to furthering the ﬁeld and the availability
of for MM is an unmet need that will require further
research and funding support.Mineral Fibers in the Environment
The group supported a range of activities as follows:
(1) increase research to identify locations where
potentially hazardous mineral ﬁbers are found in the
environment (speciﬁcally, a better understanding of the
distribution of ﬁbers in soils, and not just in the bedrock,
is needed); (2) evaluate the presence and extent of
relevant environmental exposures in areas of concern by
using activity-based sampling methods; (3) perform lung
ﬁber content analyses on tissues obtained at autopsy or
at time of surgery from residents of the area with or
without MM to help in understanding exposure disease
relationships; (4) improve characterization of ﬁbers
(size, shape, mineralogy, surface area, chemistry, etc.)
and conduct research to better understand their speciﬁc
effects on health (particularly in the setting of etiologic
research, all potentially carcinogenic mineral ﬁbers
should be studied and reported when counting ﬁbers to
assess risk for development of MM and asbestos-
associated disease, including mineral ﬁbers shorter
than 5 mm and with a diameter less than 0.25 mm,
because presently only “asbestos ﬁbers” are generally
reported and as a result of this bias it is impossible to
evaluate the overall contribution of other mineral ﬁbers,
such as NOA, to MM); (5) as another approach to doc-
umenting relevant environmental exposures to mineral
ﬁbers, perform studies using sentinel animals such as
wild rats or other animal species to measure ﬁbers in
lungs in areas where environmental exposure is sus-
pected; (6) increase understanding of human behaviorsthat cause ﬁbers to become airborne, such as off-road
vehicle recreation, housing development, and road con-
struction, and use existing information and develop
more comprehensive land management and behavior
modiﬁcation strategies to reduce human exposure to
carcinogenic ﬁbers; and (7) study unique situations of
high risk for MM without apparent mineral ﬁber expo-
sure, such as that reported in Eastern China.
Environmental Exposure and Mesothelioma
The group was in support of the idea that the
epidemiological indicators of possible environmental
exposure or genetic risk, or both, as the cause of MM in a
deﬁned population include the following: (1) a male-to-
female ratio close to 1:1, (2) an excess of MM in in-
dividuals younger than 55 years at diagnosis; and (3) a
pleural-to-peritoneal ratio close to 1:1.
When confronted with these ﬁndings (such as in
Cappadocia, Libby, southern Nevada, New Caledonia, and
most recently China), one should have a high index of
suspicion that the causes of MM are either environ-
mental, genetic, or a combination of both (i.e., gene-
environment interaction, as observed in Cappadocia).
Once the causes of MM have been identiﬁed, these co-
horts are excellent candidates for interventions to pre-
vent further exposures and for early disease detection to
reduce MM in future generations and improve disease
outcomes for at-risk individuals.
Biomarkers
The group unanimously supported continued efforts
to identify and document effectiveness and validate
biomarkers used for early detection of MM. In the case of
HMGB1, validation studies are needed to verify that high
levels of total HMGB1 can identify individuals exposed to
asbestos and that among them, the hyperacetylated form
of HMGB1 identiﬁes those in whom MM has developed.
Clinical Interventions
The group unanimously agreed that additional
research and support of clinical trials with novel agents
and immunotherapies are greatly needed. Multidisci-
plinary randomized trials in the surgical settingwith novel
agents or immunotherapies combined with trimodality
treatment should be supported, and resectable patients
should be encouraged to participate in these trials. In the
unresectable setting, as platinum-pemetrexed is the only
FDA-approved regimen, patients should be directed to
consider enrollment in novel therapeutic trials.
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